DESCRIPTION :

Moxezar- KT is a combination brand of topical opthamic preparation Moxifloxacin HCI 0.5% w/n and Ketorolactromethamine 0.4% w/n Moxifloxacin is an 8- methoxy fluroquinotone anti-infective with a diazabicyclonony Ring at the C7 position. CLINICAL PHARMACOLOGY.

MOXIFLOXACIN

Microbiology : The antibacterial action of moxifloxacin result from inhibition of the Toposomerase  II(DNA gyrase) and toppisomerase IV. DNA gyrase is an essential is An enzyme known to play a key role in the partitioning of the chromosomal DNA during Bacterial   cell   division .  The  mechanism  of  action  for  quinolones  ,  including Moxifloxacin, is different from that of macrodes , aminoghycosides or tetracyclines.Therefore,  moxifloxacin may be active against pathogens that are resistant to these  Antibiotics. There is no cross – shown to be active against most strains of the following Microorganisms.Anaerobic microorganisms: Fusobacterium species, Prevotella species.  KETOROLAC  TROMETHAMINE  is a nonsteroidal anti-inflammatory drug which has  Demonstrated analgesic and anti-inflammatory activity. The mechanism of its action is  Thought to be due to its ability to inhibit proslaglandin  osynthesis.Prostaglandins Have been shown in many animal models to be mediators of certain kinds of  Intraocular inflammation. In studies performed in animal eyes,prostanglandins have  Been shown to produce disruption of the blood-equeous humor barrier, wasodilation,  Increased vascular permeability, leukocytosis and increased intraccular pressure. Prostanglandins also appear to play a role in the miotic response produced during ocular surgery by constricting the iris sphincter independently of cholinergic mechanism. Ocular administration pf Ketorotac tromethaminer reduces prostanglandin E2(PGE2)levels in a aqueous humor.

INDICATIONS :

Moxezar-KT is indicated for the treatment of ocular infection and inflammation caused to susceptible strains of organisms mentioned above.

CONTRAINDICATIONS:

Moxezar – KT is contraindicated in patients with a history of hypersensitivity to moxifloxacin to other quinolones, Ketorolacor to any of the components in this formulation.

WARNING :

Use the solution within one month after opening the vial.FOR EXTERNAL USE ONLY. NOT FOR INJECTION PRECAUTIONS.

If superinfection occurs, discontinue use and institute altermative therapy.Whenever clinical judgement dicates.the patient should be examined with the aid of staining.Patients should be advised not to wear contact lenses if they have signs and symptoms of bacterial conjunctivitis.

DRUG INTERACTIONS:

Invitro studies indicate that moxifloxacin does not inhibit CYP3A4 , CYP2D6 ,CYP2C9 , CYP2C19 or CYP1A2. Indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes. Pregnancy: Since there are no adequate and well- controlled studies in pregnant women , Moxezar-KT should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

---

---

---